Thyroid Cancer Coverage from Every Angle
Advertisement
Advertisement

Lori J. Wirth, MD, on RET-Altered Thyroid Cancer: Results From a Study on Selpercatinib

Posted: Monday, January 1, 0001

Lori J. Wirth, MD, of Massachusetts General Hospital, discusses registrational results from a study of a selective RET inhibitor in patients with RET fusion–positive disease.

Advertisement
Advertisement


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.